Table 1.
Characteristics of studies included in systematic review of cannabinoids for chemotherapy induced nausea and vomiting
| Setting | Chemotherapy | Active v control (No of patients)* | Oxford score (random/blinding/ drop outs)8 |
|---|---|---|---|
| Adults, small cell bronchial carcinoma33 | Doxorubicin, cyclophosphamide, methotrexate, vincristine, etoposide | Nabilone 2 mg×2 (27) v prochlorperazine 10 mg×3 (30) | 1/2/1 |
| Children, age 3.5 to 17.8 years, various paediatric malignancies34 | Doxorubicin, cyclophosphamide, fluorouracil, methotrexate, vincristine, etoposide | Nabilone 1-4 mg (30) v prochlorperazine 5-20 mg (30) | 1/2/1 |
| Adults, osteogenic sarcoma35 | High dose methotrexate | Dronabinol 10 mg/m2×4 (15) v placebo (15) | 1/2/1 |
| Adults, various tumours36 | Doxorubicin, cytoxane | Dronabinol 10 mg/m2×4 (8) v placebo (8) | 1/2/1 |
| Adults, solid tumours37 | Cyclophosphamide, mustine | Dronabinol 12 mg/m2×2 (35) v metoclopramide 4.5 mg/m2×1 intravenous (35) v thiethylperazine 6.6 mg/m2×3 (35) | 1/2/0 |
| Adults, adenocarcinoma of the ovary, germ cell tumours38 | Doxorubicin, cisplatin, cyclophosphamide, methotrexate, vincristine | Nabilone 1 mg×5 (37) v metoclopramide 1 mg/kg×5 intravenous (39) | 1/2/0 |
| Children <17 years, various tumours39 | Cisplatin, cyclophosphamide, vincristine | Nabilone 1-3 mg (18) v domperidone 15-45 mg (18) | 1/2/1 |
| Adults, 15 to 74 years, various tumours40 | Bleomycin, cisplatin, cyclophosphamide, vincristine | Nabilone 2 mg×4 (80) v prochlorperazine 10 mg×4 (80) | 1/2/1 |
| Adults, 17 to 69 years, various tumours29 | Bleomycin, cyclophosphamide, vincristine | Nabilone 2 mg×2 (50) v placebo (50) | 1/2/1 |
| Adults, median age 61 years, gastrointestinal tumours41 | Doxorubicin, fluorouracil, vincristine | Dronabinol 15 mg×2 (38) v prochlorperazine 10 mg×2 (41) v placebo (37) | 1/2/1 |
| Women, various gynaecological tumours42 | Doxorubicin, cisplatin, cyclophosphamide | Nabilone 1 mg×3 (18) v chlorpromazine 12.5 mg×1-2 intramuscular (18) | 1/2/1 |
| Adults 39 to 73 years, various tumours43 | High dose cisplatin | Dronabinol 10 mg/m2×5 (15) v metoclopramide 10 mg/kg×5 intravenous (15) | 1/2/1 |
| Adults, median age 33 (range 15 to 74) years, various tumours44 | Bleomycin, cyclophosphamide, cisplatin, vincristine | Nabilone 2 mg×3-4 (113) v prochlorperazine 10 mg×3-4 (113) | 1/2/1 |
| Adults, mean age 50 (range 17 to 80) years, various tumours45 | Cisplatin, cyclophosphamide, fluorouracil, vincristine | Levonantradol 0.5 mg×3 intramuscular (27) v levonantradol 0.75 mg×3 intramuscular (28) v levonantradol 1.0 mg×3 intramuscular (26) v chlorpromazine 25 mg×3 intramuscular (27) | 1/0/0 |
| Adults aged 18 to 70 years, various tumours46 | Doxorubicin, cisplatin, cyclophosphamide, vincristine | Nabilone 2 mg×2 (18) v prochlorperazine 10 mg×2 (18) | 1/0/1 |
| Adults aged 20 to 58 years, various tumours47 | Doxorubicin, cisplatin | Nabilone 2 mg×2 (24) v placebo (24) | 1/1/1 |
| Adults, Hodgkin's or non-Hodgkin's lymphoma48 | Vincristine, chlormethine | Dronabinol 10 mg/m2×2 (11) v placebo (11) | 1/2/0 |
| Adults aged 20 to 68 years, various tumours49 | Cisplatin (not high dose) | Dronabinol 10 mg×4 (17) v prochlorperazine 10 mg×4(20) v dronabinol 10 mg×4 plus prochlorperazine 10 mg×4(17) | 1/1/1 |
| Adults, 50th centile = 57 years, various tumours50 | Doxorubicin, cisplatin, cyclophosphamide, fluorouracil, methotrexate, vincristine | Nabilone 2 mg×2 (36) v placebo (36) | 1/1/0 |
| Adults aged 18 to 69 years, various tumours, history of emesis due to chemotherapy51 | Cyclophosphamide, doxorubicin, fluorouracil, vincristine | Dronabinol 15 mg/m2×6 (36) v prochlorperazine 10 mg×6 (36) | 1/0/0 |
| Adults, mean age 41-45 years, various tumours52 | Cisplatin, doxorubicin | Dronabinol 10 mg×4 (average) (37) v haloperidol 2 mg×5 (average) (36) | 1/2/0 |
| Adults aged 19 to 45 years, testicular cancer53 | Doxorubicin, cisplatin | Nabilone 2 mg×2 (20) v alizapride 150 mg×3 (20) | 1/0/0 |
| Adults aged 48 to 78 years, lung cancer54 | Doxorubicin, cisplatin, cyclophosphamide, vincristine | Nabilone 1 mg×2 (24) v prochlorperazine 7.5 mg×2 (24) | 1/2/1 |
| Adults aged 22 to 71 years, various tumours55 | Cyclophosphamide, doxorubicin, fluorouracil | Dronabinol 7 mg/m2×4 (55) v prochlorperazine 7 mg/m2×4 (55) v placebo (55) | 1/2/1 |
| Adults aged 21 to 66 years, various tumours56 | Doxorubicin, cisplatin | Nabilone 1 mg×3 (19) v domperidone 20 mg×3 (19) | 1/1/1 |
| Adults aged 18 to 76 years, various tumours57 | No data | Dronabinol 15 mg or 10 mg/m2×3 (20) v placebo (20) | 1/2/1 |
| Children and adults, aged 9 to 70 years, various tumours58 | Cisplatin, cyclophosphamide, methotrexate | Dronabinol 15 mg or 10 mg/m2×3 (73) v prochlorperazine 10 mg×3 (73) | 1/2/1 |
| Adults aged 19 to 65 years, various tumours59 | Cisplatin | Nabilone 2 mg×2 (37) v prochlorperazine sr 10 mg×2 (37) | 1/1/1 |
| Adults aged 18 to 82 years, various tumours60 | Various | Dronabinol 7.5 to 12.5 mg×3 (172) v prochlorperazine 10 mg×3 (181) | 2/1/1 |
| Adults aged 18 to 81 years, various tumours61 | Doxorubicin, cisplatin | Nabilone 2 mg×2 (84) v placebo (84) | 1/2/1 |
*
Drugs taken orally unless stated otherwise.